Keymen Pharmaceuticals established in 1973 with Keymen Ecza Depoculuk ve Ticaret Ltd. Sti. name and operates under DMT Group.
Foundation of DMT group began with the establishment of Dr.Mustafa Topal’s first personal firm in 1965 and with establishment of Ecz.Perihan Topal Import-Export-Representation firm in 1970. Starting inn 1966, the firm handled the importation & distribution of special medicines of Dr.Anna Arslan from Romaina and medical equipment from USSR. During visits to East European countries, Dr.Mustafa Topal saw that high attention was given to public health services, and that products for public health in this region were very cheap. After investigating public health products further, Keyman began to cooperate with the Institute of Immunology and Virology Torlak in Belgrade, Serbia, and the Institute of Immunology Inc in Zagreb, Croatia, for the sales of vaccines and antisera in Turkey, collaboration that continue today.
Contact Details
Keymen İlaç Sanayi ve Ticaret A.Ş.
Şehit Gaffar Okkan Cad. No: 40
Gölbaşı 06830 ANKARA
Tel: 0 312 485 37 60
Fax: 0 312485 37 61
Keymen İlaç Sanayi ve Ticaret A.Ş.
Çamlık Mah. İkbal Cad. Dinç Sok. No:25
Ümraniye İSTANBUL
Tel: 0216 415 03 30
Fax: 0 216 415 03 27
A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s…
A roundup of the latest pharma and healthcare news from Turkey including Roche Turkey’s digital platform for HCPs and patients, big pharma’s aid to earthquake victims, the Scientific and Technological…
The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the…
After its best financial year to date – posting revenues of USD 27.3 billion in 2021 – Gilead has said yes to localization in Turkey. The California-based company, known for…
Turkey’s pharma market, the 18th largest in the world and valued at USD 7 Billion in 2020, has seen steady growth over the past few years due to favorable healthcare…
With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars. The share of biotechnological…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive…
When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in…
As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple…
Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items…
There are perhaps no two words that better summarize the last few years in Turkish pharma than localization and pricing. But after years of investment and struggles, the country’s priorities…
See our Cookie Privacy Policy Here